A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Fitch expects US sales of patented drugs to rise 5.3% year-over-year to US$327.3B in 2022, increase to US$371.9B in 2026; patented drug market is over four times the size of generic drug sub-sector, more than 10 times the size of OTC medicine sub-sector

ViiV Healthcare announces FDA approval of Triumeq PD, a dispersible single-tablet treatment regimen for children living with HIV-1

Teva Pharmaceuticals announces settlement agreement with Attorney General of Florida related to opioid-related claims; Teva will pay US$177M over 15 years and will provide lifesaving Narcan nasal spray valued at US$84M over 10 years

AstraZeneca announces approval in Japan for Ondexxya for patients taking Factor Xa inhibitors, which help prevent blood clots but can lead to uncontrolled bleeding; Ondexxya quickly reverses Factor Xa inhibitors in patients experiencing acute bleeding

Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count